Valeo Financial Advisors LLC bought a new position in shares of Masimo Co. (NASDAQ:MASI) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 497 shares of the medical equipment provider’s stock, valued at approximately $69,000.
Several other institutional investors also recently made changes to their positions in the company. West Oak Capital LLC acquired a new position in Masimo in the 1st quarter valued at approximately $28,000. Claybrook Capital LLC bought a new position in Masimo in the 4th quarter valued at $25,000. Ruggie Capital Group bought a new position in Masimo in the 4th quarter valued at $33,000. Financial Gravity Companies Inc. bought a new position in Masimo in the 4th quarter valued at $49,000. Finally, Quantamental Technologies LLC bought a new position in Masimo in the 4th quarter valued at $43,000. 83.16% of the stock is currently owned by institutional investors.
MASI has been the topic of a number of recent research reports. Zacks Investment Research lowered Masimo from a “hold” rating to a “sell” rating in a research report on Thursday, January 10th. BidaskClub upgraded Masimo from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 31st. Needham & Company LLC reiterated a “buy” rating and issued a $139.00 price objective on shares of Masimo in a research report on Friday, February 1st. Piper Jaffray Companies reiterated an “overweight” rating and issued a $140.00 price objective on shares of Masimo in a research report on Wednesday, February 27th. Finally, BTIG Research downgraded Masimo from a “buy” rating to a “neutral” rating and set a $134.50 price target on the stock. in a research note on Tuesday, April 16th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $149.75.
Masimo (NASDAQ:MASI) last released its quarterly earnings results on Monday, May 6th. The medical equipment provider reported $0.79 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.75 by $0.04. Masimo had a return on equity of 19.53% and a net margin of 22.55%. The firm had revenue of $231.70 million for the quarter, compared to the consensus estimate of $223.67 million. During the same quarter last year, the business posted $0.75 EPS. The company’s revenue for the quarter was up 8.8% on a year-over-year basis. Research analysts expect that Masimo Co. will post 3.08 EPS for the current year.
In other news, insider Jon Coleman sold 2,000 shares of the firm’s stock in a transaction dated Wednesday, February 27th. The stock was sold at an average price of $135.00, for a total value of $270,000.00. Following the completion of the transaction, the insider now owns 13,201 shares in the company, valued at approximately $1,782,135. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Steven Barker sold 5,877 shares of the firm’s stock in a transaction dated Monday, February 25th. The shares were sold at an average price of $130.00, for a total value of $764,010.00. Following the completion of the transaction, the director now owns 70,709 shares of the company’s stock, valued at approximately $9,192,170. The disclosure for this sale can be found here. Insiders sold a total of 33,722 shares of company stock worth $4,582,310 in the last three months. Company insiders own 11.50% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was originally published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://www.baseballdailydigest.com/news/2019/05/09/valeo-financial-advisors-llc-takes-69000-position-in-masimo-co-masi.html.
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
See Also: Why are gap-down stocks important?
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.